Drug Trial Radar · NCT06940739
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
Jun 2032
Study completion Jul 2032
Sponsor
- Lead sponsor
- Iovance Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Conditions
- Unresectable Melanoma
- Metastatic Melanoma
- Ocular Melanoma
Interventions
IOV-3001Biological
IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Up to 30 days
- Recommended Dose for Phase 2Time frame: Up to 30 days
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
SCRI Oncology Partners- Denver
Denver, Colorado · Recruiting
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Greenslopes Private Hospital
Greenslopes, Queensland, Australia · Recruiting
Hollywood Private Hospital Ramsay
Nedlands, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.